How long should Clopidogrel be prescribed for patients with drug-eluting stents?

Clopidogrel should be prescribed for a duration of 12 months or longer for patients with drug-eluting stents due to the risk of stent thrombosis. Drug-eluting stents are designed to release medication that helps prevent the re-narrowing of the artery; however, patients remain at risk for thrombotic events during the first year following stent placement. Studies have shown that extended antiplatelet therapy significantly reduces the likelihood of these events by maintaining adequate platelet inhibition.

The recommendation for a duration of at least 12 months aligns with guidelines from various cardiology associations, which emphasize the importance of dual antiplatelet therapy (DAPT) in the first year to optimize stent patency and prevent acute coronary syndromes. Continuing Clopidogrel beyond 12 months may be appropriate in certain high-risk patients, particularly those with additional thrombotic risk factors, but the standard minimum duration is typically 12 months or longer.

While shorter durations, such as 30 days or 6 months, may be considered in select low-risk cases or based on physician discretion, adhering to the 12 months is essential for the majority of patients to ensure adequate protection against complications. The recommendation for a lifetime of Clopidogrel